The pros and cons of selling to private equity come down to a single trade: a sponsor will usually pay a higher multiple than any other financial buyer and will fund it in cash at close, and in exchange it takes the debt capacity of your company, the consent rights over how it is run, and roughly seven years of your patience before the money you left in the deal comes back. Whether that is a good trade depends almost entirely on how much of the headline price you actually receive at closing, and on whether you were planning to keep working.
What follows is the ledger, both sides, with numbers. If you want the mechanics of running the process, read how to sell a business to private equity. If you have already signed and want to know what the next few years look like, read what happens after private equity buys your company. This page is the decision itself.
The case for selling to private equity
The multiple is real, and it rises steeply with size
Sponsor pricing in the lower middle market is well documented. GF Data reported that average purchase price multiples in the middle market rose to 7.5x trailing twelve-month adjusted EBITDA in the third quarter of 2025, up from 6.9x in the second quarter, even as completed deal count fell to 66 in the quarter and 211 year to date, a 27% drop against the same period in 2024. Prices held up while volume did not, which tells you something about how much capital is chasing good companies.
The more useful number for an owner is how sharply the multiple scales with enterprise value. GF Data's figures for the first nine months of 2025, compiled by size bracket, run like this:
| Enterprise value | Average EBITDA multiple |
|---|---|
| $10M – $25M | 6.4x |
| $25M – $50M | 6.8x |
| $50M – $100M | 8.3x |
| $100M – $250M | 10.3x |
A company growing from $4 million of EBITDA to $8 million does not double in value; at those multiples it roughly triples. That size premium is the single strongest argument for bringing in sponsor capital rather than selling outright today, and it is the argument a good banker will make first. The mechanics behind those numbers are in how private equity firms value a company, and you can run your own range in the business valuation calculator.
The money exists and is under pressure to move
Bain & Company's 2026 global private equity outlook puts global buyout dry powder at $1.3 trillion, most of it from 2022–23 vintage funds, against 2025 deal value of $904 billion across 3,018 transactions. Committed capital has a shelf life. A fund in year four of its investment period is a motivated buyer in a way a strategic acquirer never is, and that motivation is what a competitive process converts into price.
You can take most of the money off the table without leaving
The structural advantage of a sponsor over a strategic buyer is that a sponsor wants you to stay invested. A majority recapitalization lets an owner convert 70–80% of the value of the business to cash now and keep the rest working, which is a genuinely different outcome from a full sale to a competitor. The details of how that residual stake behaves are covered in rollover equity and the second bite and in minority recapitalization.
You get institutional capability you were not going to hire
A decent sponsor arrives with a CFO bench, a pricing analyst, an acquisition pipeline, and lenders who return calls. For an owner-operated company that has never had a board, that is real. It is also, as the next section explains, the same apparatus that decides what the company does next.
The case against
The headline number is not the number
This is the part most owners get wrong, and it is arithmetic rather than opinion. SRS Acquiom's deal terms study, drawn from more than 2,200 private-target acquisitions that closed from 2019 to 2024, found that earnouts pay roughly 21 cents on the dollar across all deals with earnouts outside life sciences, that 68% of earnout deals use multiple performance metrics, that more than three-quarters of deals carry a special-purpose escrow for the purchase price adjustment alone, and that the median indemnification survival period is twelve months.
Put that against a made-up company. Call it $5 million of adjusted EBITDA sold at 7.0x, a $35 million enterprise value, structured the way lower-middle-market deals routinely are: 70% cash at close, 20% rollover, 10% earnout. Assume a near-zero tax basis, the top 20% long-term capital gains rate and the 3.8% net investment income tax, for a 23.8% combined federal rate.
| Hypothetical $35M deal | Amount |
|---|---|
| Headline enterprise value ($5M × 7.0x) | $35.00M |
| Cash at close (70%) | $24.50M |
| Rollover equity (20%), at risk for the hold | $7.00M |
| Earnout (10% maximum) | $3.50M |
| Earnout at the 21-cents-on-the-dollar average | $0.74M |
| Federal tax at 23.8% on cash plus expected earnout | ($6.01M) |
| After-tax money actually in hand | $19.23M |
Those are invented numbers on an invented company, and they ignore state tax, working capital adjustments and transaction fees, all of which push the figure down further. But the shape is right: a $35 million headline becomes about $19 million of realized, after-tax proceeds, roughly 55% of the number in the press release, with $7 million left riding on someone else's exit timing. Owners who benchmark offers on headline enterprise value are comparing the wrong quantity.
The debt lands on your company, not on the fund
A leveraged buyout is financed against the cash flow of the business being bought. On the same hypothetical, a sponsor funding half of a $35 million purchase with debt leaves $17.5 million of borrowings on a company earning $5 million, roughly $1.75 million of annual interest at a 10% blended cost. That is 35% of EBITDA leaving as interest before taxes, capital expenditure or working capital. The company is not less profitable afterwards; it is less free. How private equity actually finances a buyout walks through the capital stack line by line.
You probably will not run it to the finish
AlixPartners' eleventh annual private equity leadership survey, covering 174 private equity professionals and 253 portfolio company executives, found that 65% of private equity firms reported CEO turnover during the holding period and that only 9% said they rarely replace CEOs. Thirty-eight percent of portfolio company executives worried about losing their jobs to the disruption. If your plan is to sell 80% and run the business for another decade, the base rate is against you.
Seven years, and the exit is not guaranteed
The three-to-five-year hold in the pitch deck is no longer what happens. Bain puts the average holding period at exit at roughly seven years in 2025, against five to six years through the 2010s, and counts a backlog of about 32,000 unsold portfolio companies worth $3.8 trillion. Distributions ran at 14% of net asset value in 2025, the fourth consecutive year below 15%. The AlixPartners survey found nearly half of respondents reporting difficulty finding buyers. Your rollover is a claim on an exit that the industry as a whole is currently struggling to produce.
Control changes hands at close, whatever the percentage says
Minority and majority deals both come with a consent list: debt, acquisitions, budgets, senior hires, distributions and any sale of the company. Ownership percentage is not the variable that matters. What a minority private equity stake really controls goes through which items on that list are genuinely negotiable before signing.
Who selling to private equity actually fits
It fits an owner who wants out, has a management team that can run the company without them, and values certainty of cash at close above the size of the eventual second bite. It fits a company below the size premium that genuinely needs outside capital to buy its way up the multiple ladder. It fits a founder who is energized rather than exhausted by a board, a reporting cadence and an acquisition program. And it fits anyone whose realistic alternative is no buyer at all.
Who should look elsewhere
If the goal is liquidity without a new boss, the sponsor model is an expensive way to get there. Owners in that position generally have better options: an internal or family succession, a management buyout financed against the business, an ESOP, or a straight debt recapitalization. The full menu, costed side by side, is in alternatives to selling to private equity and in our guide to every exit option.
Frequently asked questions
Is selling to private equity worth it? It is worth it when the after-tax cash at close, not the headline enterprise value, clears what you need, and when you are genuinely willing to operate under a board for the remainder of the hold. Run the cash-at-close number before you run anything else.
How much of the price do I get at closing? Less than the headline. Typical lower-middle-market structures hold back value through rollover, escrow and earnout, and earnouts across thousands of private-target deals paid about 21 cents on the dollar.
Does private equity pay more than a strategic buyer? Often, for financial reasons rather than sentimental ones. Sponsors have committed capital with a deadline and can underwrite leverage precisely. A strategic buyer with real synergies can beat them, but only for a company that fits its plan.
How long will private equity own my company? Plan for about seven years, not three to five. Average holds at exit have lengthened and the industry is carrying tens of thousands of companies it has not been able to sell.
Can I keep control and still take money off the table? Only with a structure designed for it. A minority sale still comes with a consent list, so read the shareholders' agreement, not the ownership percentage.
Sources
- GF Data – "Q3 Reports: Middle-Market M&A Slows, Valuation Multiples Rise"
- CapitalPad – lower middle market EBITDA multiples by deal size, compiled from GF Data
- Bain & Company – "Private Equity Outlook 2026: Gaining Traction"
- SRS Acquiom 2025 M&A Deal Terms Study, as reported by PE Professional
- AlixPartners – 11th Annual Private Equity Leadership Survey
- IRS – Topic No. 409, Capital Gains and Losses
- IRS – Net Investment Income Tax
The bottom line
Selling to private equity is neither the trap the internet says it is nor the clean exit the pitch deck implies. It is a financing transaction with a defined shape: a strong multiple, a large share of it deferred, the company's own borrowing capacity spent to fund it, and a board that sets the agenda until an exit that now takes about seven years to arrive. Owners who go in with the after-tax cash-at-close number in front of them make good decisions. Owners who go in with the enterprise value in front of them are frequently surprised.
There is a third position worth costing out before you choose. An Independent Buyout makes your existing leadership team the buyer, financed against the business itself, at a valuation set the same way a sponsor would set it — without an outside fund holding the consent list or the exit clock. The comparison is laid out in the IBO versus private equity numbers.
If your company does $3M+ in EBITDA and you want the pros and cons of each structure priced out against your actual financials, talk to IBO Advisors.
Curious whether an Independent Buyout fits your business?
Learn More